Telitacicept for active primary Sjögren's disease
Treatments studied
Part of Bones, joints & muscles, Eyes & vision, Immune system & allergy, Mouth & dental, Skin clinical trials.
This study tests an investigational drug called telitacicept for people with active primary Sjögren's disease. The goal is to see if it can reduce symptoms like joint pain, fatigue, and swelling better than a placebo.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with primary Sjögren's disease (not caused by another autoimmune condition).
- You have a positive blood test for anti-SSA (Ro) antibodies.
- Your disease is moderately to highly active (score of 5 or more on the ESSDAI scale).
- You do not have another autoimmune disease like lupus or rheumatoid arthritis that could better explain your symptoms.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This clinical trial tests a new drug called telitacicept for people who have both Sjögren's syndrome and interstitial lung disease. The drug aims to reduce the immune system's attack on your body and may help improve lung symptoms.
This trial tests an investigational drug called IBI355 for people with moderate-to-severe Sjögren's disease. It aims to reduce inflammation and improve symptoms by targeting part of the immune system.
This trial tests a new drug called telitacicept for people with lung scarring caused by connective tissue diseases. It aims to see if the drug can improve lung function and slow down the disease progression.
This trial tests a new drug called telitacicept for people with recently diagnosed, rapidly progressing systemic sclerosis (scleroderma). It aims to see if the drug can slow down skin thickening and other symptoms.
This study tests a new medicine called ICP-488 for people with primary Sjögren's syndrome. It may help reduce symptoms like dry eyes and dry mouth by calming the immune system. The trial lasts about 48 weeks and includes regular check-ups.
This study tests the safety of a daily pill called Tofacitinib for adults with mild-to-moderate Sjögren's disease. It aims to see if this drug helps manage symptoms when other treatments haven't worked well.
Hear when a new Primary Sjogren's Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.